Ivermectin-Induced Acute Psychosis in Patients Infected With COVID-19 Pneumonia

Goyal, Lokesh; Pandit, Ramesh; Pandit, Trupti; Ajmera, Kunal; Lusins, John O; Islam, Shah

doi:10.7759/cureus.26141

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the disease period, hydroxychloroquine, oseltamivir, and azithromycin were included in the recommendations of the World Health Organization, and we applied these treatments to our patients. However, among the treatment modalities, these drugs are no longer among the treatment recommendations because of their side effects or because of their ineffectiveness [ 30 ]. Especially, patients in the ICU benefited from antibiotics, which showed that bacterial superinfections play an important role in the progress of COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Cytokine Profile of Children With COVID-19: A Report From Turkey

Dalkıran¹,

Kara²,

Ünsal³

et al. 2023

Cureus

View full text Add to dashboard Cite

Background We aimed to analyze the expression of infection-related biomarkers and inflammatory cytokines in laboratory-confirmed cases and compare the differences between clinically severe and non-severe ones. Method We randomly selected 35 patients who were hospitalized with the diagnosis of coronavirus disease 2019 (COVID-19). Blood serum was obtained at the time of admission to the hospital, on the third to the fifth day, and at the time of discharge. Result The median age of our patients was 56.5±69.7 months (range: 1-205 months). The mean pro-B-type natriuretic peptide (pro-BNP) was significantly higher at the time of admission than on the third to the fifth day of illness. The mean pro-B-type natriuretic peptide levels at three time points were significantly higher in patients with severe cases than in mild-moderate cases. However, there was no significant difference between the clinical severity with regard to the cytokine levels at disease onset and recovery. Conclusion In the study, it was shown that cytokines play an important role in the pathogenesis of COVID-19. Therefore, it may be beneficial to use agents such as tocilizumab in the treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Cytokine Profile of Children With COVID-19: A Report From Turkey

Dalkıran¹,

Kara²,

Ünsal³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Antiretrovirals such as remdesivir have emergency use authorization (EUA) for infants > 28 days and > 3.5 kg [ 20 ], while Paxlovid and monoclonal antibodies have EUA for children 12 years and older [ 21 ]. A double-blind study comparing ivermectin vs. placebo showed decreased viral load in COVID-19 adult patients, but the use of the same has not been evaluated adequately with the associated side effects [ 22 - 23 ]. The Centers for Disease Control and Prevention (CDC) has declared vaccination for COVID-19 safe for pregnant women, and it is prudent to vaccinate expecting mothers in the last trimester so the fetus can have the passive transfer of protective antibodies, given the information that vaccine-based immune response is maximum for three months duration [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Possible COVID-19 Maternal-to-Neonate Vertical Transmission in a Case of Early Neonatal Infection

Pandit¹,

Pandit²,

Bhattar³

2022

Cureus

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a disease caused by a novel strain of coronavirus and has resulted in a global pandemic. Information regarding the COVID-19 pathophysiology and its long-term impacts on humans is yet to be found. The knowledge about the COVID -19 infection's effects on the fetus is limited. The maternal to fetal transmission during various trimesters is not adequately studied. We present a case concerning maternal-to-fetal vertical transmission focusing on congenital infection.

show abstract

“…During the initial phase of the COVID-19 pneumonia pandemic, it was thought that ivermectin might be helpful in patients infected with COVID-19 pneumonia, but this was later proven to be false due to its severe risks/side effects. The Infectious Disease Society of America (IDSA) recommends against the use of ivermectin for COVID-19 pneumonia [ 34 ]. Future studies should focus on the quality and RCT study design in patients with varying degrees of severity.…”

mentioning

confidence: 99%

Perspective: repurposed Drugs for COVID-19

2022

View full text Add to dashboard Cite

IntroductionThe article aims to emphasize the necessity of proper research design, both scientifically and ethically, in order to provide good evidence for physicians to base their decisions on when prescribing drug treatment.Material and methodsResearch articles and guidelines related to therapy of COVID-19 were searched from the PubMed database.ResultsOnly remdesivir and tocilizumab are medicines that have been approved by the US FDA’s decision to approve their clinical use in moderate and severe COVID-19.ConclusionsFavipiravir, ivermectin and andrographolide need further well-conducted research to confirm the efficacy and safety against COVID-19 at different stages.

show abstract

Ivermectin-Induced Acute Psychosis in Patients Infected With COVID-19 Pneumonia

Cited by 3 publications

References 13 publications

Clinical and Cytokine Profile of Children With COVID-19: A Report From Turkey

Clinical and Cytokine Profile of Children With COVID-19: A Report From Turkey

Possible COVID-19 Maternal-to-Neonate Vertical Transmission in a Case of Early Neonatal Infection

Perspective: repurposed Drugs for COVID-19

Contact Info

Product

Resources

About